Elenita Davidson

PURPOSE: Over a 5-year or 10-year period, between 6% and 15% of germline cancer genetic variants undergo reclassification. Up-to-date interpretation can clarify a variant's clinical significance and guide patient management. As the frequency of reclassifications increase, the issue of whether, how, when, and which providers should recontact patients with information about reclassification becomes important.

INTRODUCTION Health care providers who order genetic tests regularly receive amended reports describing a change in the variant’s pathogenicity and clinical implication. Approximately 40% of genetic counselors (GC) who practice in oncology and 12.5% of oncologists who order/use germline genetic tests report that they “often” receive such amended reports1 in their practice.